Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...4546474849505152535455...401402»
  • ||||||||||  Determinants of oxidative stress and antioxidant status in COPD (PS-11; Poster board no. 2) -  May 31, 2024 - Abstract #ERS2024ERS_475;    
    Our findings in this study reveal a positive correlation between total antioxidant capacity and signs of sarcopenia. On the other hand, oxidative stress was only associated with increased levels of inflammatory biomarkers.
  • ||||||||||  Tyrisa (darapladib) / GSK
    Predictive and therapeutic value of lipoprotein-associated phospholipaseA2 in sarcopenia in chronic obstructive pulmonary disease (PS-6; Poster board no. 16) -  May 31, 2024 - Abstract #ERS2024ERS_387;    
    Darapladib treatment (25 and 50 mg/kg) rescued CS-induced musclemass loss and muscle functions. Darapladib could reverse CS?induced increase of atrogin?1 and MuRF1 expression and activation of inflammatory factors, oxidant enzymes and NF-?B signaling.ConclusionsSerum Lp-PLA2 level was significantly elevated in patients with COPD, especially in sarcopenic patients with COPD, which could be a potential indicator for sarcopenia.
  • ||||||||||  Changes in body composition in patients with ischaemic heart disease and post-COVID-19 syndrome. (PS-1; Poster board no. 11) -  May 31, 2024 - Abstract #ERS2024ERS_302;    
    Darapladib could reverse CS?induced increase of atrogin?1 and MuRF1 expression and activation of inflammatory factors, oxidant enzymes and NF-?B signaling.ConclusionsSerum Lp-PLA2 level was significantly elevated in patients with COPD, especially in sarcopenic patients with COPD, which could be a potential indicator for sarcopenia. 528 patients were evaluated, age was 54.6
  • ||||||||||  Journal:  Thbs1 regulates skeletal muscle mass in a TGF?-Smad2/3-ATF4-dependent manner. (Pubmed Central) -  May 31, 2024   
    More importantly, Thbs1-/- mice show significantly reduced levels of denervation- and caloric restriction-mediated muscle atrophy, along with blunted TGF?-Smad3-ATF4 signaling. Thus, Thbs1-mediated TGF?-Smad3-ATF4 signaling in skeletal muscle regulates tissue rarefaction, suggesting a target for atrophy-based muscle diseases and sarcopenia with aging.
  • ||||||||||  Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
    Preclinical, Journal:  The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male (Pubmed Central) -  May 31, 2024   
    At the cellular level, empagliflozin exhibits similar anti-fibrotic effects, and these effects are attenuated by Compound C and siAMPK?. Empagliflozin exhibits anti-fibrotic effects, possibly associated with the AMPK/MMP9/TGF?1/Smad signaling pathways.
  • ||||||||||  Trial completion, Trial completion date:  Insect Protein and Muscle Protein Signaling (clinicaltrials.gov) -  May 31, 2024   
    P=N/A,  N=50, Completed, 
    Moreover, inspiratory and abdominal muscle combined training showed an additional benefit of improving systemic muscle strength, mass and performance. Active, not recruiting --> Completed | Trial completion date: May 2023 --> Nov 2023
  • ||||||||||  Journal:  Parameters of body composition do not predict survival in patients with multiple myeloma undergoing autologous stem cell transplantation. (Pubmed Central) -  May 30, 2024   
    No statistically significant differences were noted in 2-year OS, PFS, or post-transplant adverse events in the body composition groups of subcutaneous adipose tissue (SAT) (low vs. high-SAT), visceral adipose tissue (VAT) (low vs. high-VAT), visceral-to-subcutaneous fat ratio (VSR) (low vs. high VSR), and sarcopenia in terms of skeletal muscle index (SMI) (non-sarcopenic vs. sarcopenic). In conclusion, adipose and muscle tissue do not limit OS or affect the PFS in patients with MM undergoing ASCT.
  • ||||||||||  Journal:  Quick and easy assessment of sarcopenia in cirrhosis: Can ultrasound be the solution? (Pubmed Central) -  May 30, 2024   
    Assessment of muscle mass by computed tomography is considered the standard of care for the diagnosis of sarcopenia, but exposure to radiation and high costs limit its application in this setting, especially for repeated assessments. We believe that ultrasound, a cheap and harmless technique also used for HCC screening in cirrhotic patients, could have an expanding role in the diagnosis and follow-up of sarcopenia in these patients.
  • ||||||||||  Journal:  Reply - Letter to the editor. (Pubmed Central) -  May 30, 2024   
    We also emphasize the areas of uncertainties and suggest potential research areas. No abstract available
  • ||||||||||  MitoQ (mitoquinone) / Antipodean
    Review, Journal:  Nutritional Strategies for Muscle Atrophy: Current Evidence and Underlying Mechanisms. (Pubmed Central) -  May 30, 2024   
    Furthermore, the study discusses the impact of a combined approach involving nutritional support and physical therapy to prevent muscle atrophy, suggests appropriate multi-nutritional and multi-modal interventions based on individual conditions to optimize treatment outcomes, and enhances the recovery of muscle function for patients. By understanding the molecular mechanisms behind skeletal muscle atrophy and implementing appropriate interventions, it is possible to enhance the recovery of muscle function and improve patients' quality of life.
  • ||||||||||  MOVEMENT-AVOIDANCE BEHAVIOUR IN OSTEOPOROTIC PATIENTS: COULD MAJOR BONE FRACTURES LEAD TO INACTIVITY AND POOR QUALITY OF LIFE? () -  May 29, 2024 - Abstract #EULAR2024EULAR_4440;    
    Our analysis confirmed that older age, lower BMI, later menarche and earlier menopause are relevant risk factors for osteoporosis and fragility fractures, also the history of recent falls is an important determinant. Moreover, this study demonstrated that subjects with osteoporosis have higher levels of movement-avoidance behaviour compared to healthy subjects, in particular if a previous fracture has been occurred, suggesting the need for a multidisciplinary approach, that includes physical activity programs.
  • ||||||||||  IMAGING TECHNIQUES IN ASSESSING THE MUSCULAR STATUS OF PATIENTS WITH CORONARY HEART DISEASE () -  May 29, 2024 - Abstract #EULAR2024EULAR_4365;    
    Table 1. The clinical and anamnestic image of a patient with stable coronary artery disease and sarcopenia is characterized by an association of reduced muscle mass with male gender, age, hypercholesterolemia, multivessel coronary disease, a long history of diabetes mellitus and angina pectoris.
  • ||||||||||  MUSCLE STRENGTH COULD BE DETERMINED BY AGE, DLCOC AND HEALTH ASSESSMENT QUESTIONNAIRE IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY () -  May 29, 2024 - Abstract #EULAR2024EULAR_4111;    
    The clinical and anamnestic image of a patient with stable coronary artery disease and sarcopenia is characterized by an association of reduced muscle mass with male gender, age, hypercholesterolemia, multivessel coronary disease, a long history of diabetes mellitus and angina pectoris. In our population of patients with systemic sclerosis, the prevalence of dynapenia was high (41%), particularly among older individuals with worse DLCOc and HAQ.
  • ||||||||||  PREVALENCE AND RISK FACTORS OF SARCOPENIA IN YOUNG ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS () -  May 29, 2024 - Abstract #EULAR2024EULAR_3863;    
    By the obtained values of regression coefficients, an increase in disease duration, DAS28-ESR, HAQ, and a decrease in weight, vitamin D25OH leads to an increased likelihood of developing sarcopenia in young adults with JIA. The prevalence of sarcopenia was high among young adults with JIA and associated with higher disease activity, articular and extra-articular damage and reduced functional capacity.
  • ||||||||||  PAIN SYNDROME, PHYSICAL ACTIVITY AND QUALITY OF LIFE IN WOMEN WITH OSTEOARTHRITIS AND SARCOPENIA () -  May 29, 2024 - Abstract #EULAR2024EULAR_3712;    
    Locomotive syndrome status was considered appropriate for the assessment of mobility function in such patients rather than physical frailty. The combination of OA and HR-SP was associated with more severe joint pain, lower function, and quality of life that requires its accounting in the management of patients with OA.
  • ||||||||||  SARCOPENIA IN RHEUMATOID ARTHRITIS: A LONG-TERM PROSPECTIVE STUDY () -  May 29, 2024 - Abstract #EULAR2024EULAR_3619;    
    In addition, there was not incidence of sarcopenia during follow-up. Baseline sarcopenia did not emerge as a risk factor for falls, fractures, or mortality in established RA patients undergoing regular treatment.
  • ||||||||||  SARCOPENIA AND SARCOPENIC OBESITY IN PRIMARY SJ () -  May 29, 2024 - Abstract #EULAR2024EULAR_3125;    
    Lower ASSM and ASMI are the predictors of limited physical activity and poorer life quality of patients with SLE. Sarcopenia/SO can affect a relevant proportion of patients with pSS and SO identifies a specific subset of pSS patients characterized by higher values of VAS pain, VAS fatigue and VAS dryness and, consequently, higher ESSPRI scores.
  • ||||||||||  UNMASKING SARCOPENIA IN AXIAL SPONDYLOARTHRITIS: A COMPARATIVE ANALYSIS OF SCREENING TOOLS () -  May 29, 2024 - Abstract #EULAR2024EULAR_2948;    
    Notably, calf circumference, SARC-CalF, and SARC-F+EBM exhibited superior screening efficacy compared to SARC-F alone, underscoring their potential as adept tools for sarcopenia identification within the ax-SpA population. This study advocates for heightened awareness and proactive management of sarcopenia in patients with axSpA.